COMPARISON
Cagrilintide vs Exenatide
5 attributes held for at least one of the two. 5 differ. Each value carries the register it came from and the date that register was read.
Answer
Cagrilintide is authorised or registered in 0 and Exenatide in 5 of the 10 registers read. Cagrilintide: highest phase Phase 3 (17 phase 3 trials, 0 with posted results). Exenatide: highest phase Phase 2. 0 registered trials include both.
States no view on which is preferable, safer or more effective. Not medical advice.
| Cagrilintide | Exenatide | |
|---|---|---|
| Registered trials differs | 66 clinicaltrials.gov · 2026-10-03 | 383 clinicaltrials.gov · 2026-10-03 |
| FDA label differs | Not checked no record of "fdaLabel" for cagrilintide | FDA-approved: Byetta openfda · 2026-10-03T17:23:44.062Z |
| EU authorisation differs | Nothing on record ema read 2026-08-31 | Withdrawn ema · 2026-10-03 |
| EU withdrawn on differs | Not checked no record of "withdrawnOn" for cagrilintide | 2024-11-20 ema · 2026-10-03 |
| ATC code differs | Not checked no record of "atcCode" for cagrilintide | A10BJ01 ema · 2026-10-03 |
SIDE EFFECTS
Most common side effects, each beside its own placebo
| Side effect | Cagrilintide | placebo | Exenatide | placebo |
|---|---|---|---|---|
| Constipation | 16.1% | 13.1% | 0.8% | 0.3% |
| Fatigue | 9.7% | 1.6% | 0.6% | 0.1% |
| Back pain | 6.5% | 3.3% | 0.5% | 0.6% |
| Nausea | 29.0% | 14.8% | - | - |
| COVID-19 | 16.1% | 13.1% | - | - |
| Diarrhoea | 16.1% | 6.6% | - | - |
| Gastrooesophageal reflux disease | 9.7% | 1.6% | - | - |
| Vomiting | 9.7% | 1.6% | - | - |
| Eructation | 6.5% | 0.0% | - | - |
| Gastroenteritis | 6.5% | 6.6% | - | - |
| Headache | - | - | 1.9% | 1.3% |
| Non-cardiac chest pain | - | - | 1.1% | 1.0% |
| Osteoarthritis | - | - | 0.9% | 1.0% |
| Dizziness | - | - | 0.8% | 0.4% |
| Dyspepsia | - | - | 0.8% | 0.3% |
| Chronic obstructive pulmonary disease | - | - | 0.7% | 0.7% |
| Sinusitis | - | - | 0.5% | 0.2% |
Trial register Cagrilintide: 1 placebo-controlled trials; Exenatide: 24. Each peptide is compared with placebo in its own trials, not with the other: a dash means the event is not in that peptide's top list. Cagrilintide side effects · Exenatide side effects
LEGAL STATUS
Approval in each country read
| Country | Cagrilintide | Exenatide | Register |
|---|---|---|---|
| United States | Not on the register | FDA-approved | Regulator FDA |
| European Union | Not on the register | Withdrawn | Regulator EMA |
| United Kingdom | Not on the register | Authorised | Regulator MHRA |
| Canada | Not on the register | Authorised | Regulator Health Canada |
| Australia | Status unknown | Status unknown | TGA |
| Switzerland | Not on the register | Not on the register | Regulator Swissmedic |
| Brazil | Not on the register | Registado | Regulator ANVISA |
| Serbia | Not on the register | Not on the register | Regulator ALIMS |
| Singapore | Not on the register | Not on the register | Regulator HSA |
| Turkey | Not on the register | Ruhsatli | Regulator TITCK |
Values reproduce public registers on the dates shown. This comparison states no view on which compound is preferable, safer or more effective. Not medical, legal or regulatory advice.
WEEKLY
Register Watch, weekly
New trials, approvals and enforcement actions. One email a week.